文献速递消化道肿瘤放疗

局部晚期直肠癌新辅助放化疗剂量递增对临床与病理缓解的影响:随机对照试验的系统综述与Meta分析

Effect of dose escalation in neoadjuvant chemoradiotherapy of locally advanced rectal cancer on clinical and pathologic Response: A Systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-02-10

该Meta分析纳入12项随机对照试验共1803例局部晚期直肠癌患者,评估新辅助放化疗剂量递增对复合完全缓解终点的影响。总体复合CR效应未达统计学显著性(RR 1.26,95% CI:0.95-1.68);在两组化疗方案一致的试验中剂量递增使CR率升高但未达统计学显著性(RR 1.46,95% CI:1.00-2.12)。剂量递增未独立显著增加严重急性毒性(RR 0.92,95% CI:0.53-1.59),毒性严重程度似与化疗方式更直接相关。

要点

  • 剂量递增对复合CR的总体效应未达统计学显著性(RR 1.26,95% CI:0.95-1.68)。
  • 化疗方案一致时剂量递增使CR率升高但未达统计学显著性(RR 1.46,95% CI:1.00-2.12)。
  • 剂量递增未独立显著增加严重急性毒性,毒性似与化疗方式更相关。

核心结论

  • 在局部晚期直肠癌新辅助放化疗中,提高放疗剂量可能适度增强肿瘤缓解,但复合完全缓解终点的总体效应未达统计学显著性。
  • 该策略与直肠癌器官功能保留的治疗框架方向一致。

研究设计与样本

  • 系统综述与Meta分析,纳入12项随机对照试验,共1803例局部晚期直肠癌患者。
  • 比较剂量递增新辅助放化疗与对照,评估复合完全缓解终点(含病理完全缓解与临床完全缓解)及毒性。

主要发现

  • 复合CR终点的总体效应未达统计学显著性(RR 1.26,95% CI:0.95-1.68)。
  • 在对照与试验组采用统一化疗方案的临床试验中,提高剂量使CR率升高但未达统计学显著性(RR 1.46,95% CI:1.00-2.12)。
  • 改变同步化疗方案的研究未显示上述获益。
  • 提高放疗剂量未独立导致严重急性毒性显著增加(RR 0.92,95% CI:0.53-1.59),毒性严重程度似与所用化疗方式更直接相关。

关键数值与推荐

  • 复合CR终点总体RR 1.26(95% CI:0.95-1.68)。
  • 统一化疗方案亚组CR的RR 1.46(95% CI:1.00-2.12)。
  • 严重急性毒性RR 0.92(95% CI:0.53-1.59)。

临床怎么用

  • 剂量递增新辅助放化疗可作为局部晚期直肠癌器官功能保留策略的候选方案,但需权衡其尚未确证的CR获益。
  • 同步化疗方案的选择与统一可能是影响CR获益和毒性严重程度的重要因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of locally advanced rectal cancer (LARC) increasingly highlights necessity of organ functionality preservation, with the achievement of a complete clinical or pathological response (CR) regarded as a fundamental treatment target. While established concurrent chemoradiation (CRT) is effective, it often results in only modest complete response rates, thus prompting exploration into the possible benefits of raising radiation dosages to boost clinical results. This meta-analysis of randomized controlled trials sought to elucidate whether dose-escalated neoadjuvant CRT augments tumor response and to evaluate its accompanying toxicity profile. By extracting data from 12 trials encompassing 1,803 patients, we discerned that the overall effect on a composite CR endpoint-incorporating both pathological and clinical complete responses-did not achieve statistical significance (RR 1.26, 95% CI: 0.95-1.68). Notably, the subgroup evaluation showed that in clinical trials with a uniform chemotherapy strategy for both control and experimental populations, raising the dosage led to an elevation in CR rates which was not statistically significant (RR 1.46, 95% CI: 1.00-2.12). Conversely, studies that altered concurrent chemotherapy did not show these benefits. Also, the assessment showed that raised radiation doses did not independently result in a marked rise in severe acute toxicity (RR 0.92, 95% CI: 0.53 - 1.59); instead, the gravity of toxicity appeared to be more directly associated with the chemotherapy methods used. These findings suggest that increasing radiation dose may modestly enhance tumor response in LARC. This technique corresponds with the progressing framework towards preserving organ function in rectal cancer.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kolahdouzan K, Nayebi Rad S, Ghalehtaki R, et al. Effect of dose escalation in neoadjuvant chemoradiotherapy of locally advanced rectal cancer on clinical and pathologic Response: A Systematic review and meta-analysis of randomized controlled trials. Clin Transl Radiat Oncol. 2026. PMID: 41717095. doi:10.1016/j.ctro.2026.101123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。